黄体期雌二醇减量不影响激素替代治疗冻融胚胎移植周期的临床结局:一项回顾性分析
该回顾性研究纳入湘雅医院生殖医学中心2011年1月至2018年6月共6035个激素替代治疗冻融胚胎移植(HRT-FET)周期,比较胚胎移植后12天起雌二醇减量组(1632个周期)与黄体期雌二醇维持常量组(4403个周期)的临床结局,发现两组生化妊娠率、临床妊娠率、着床率和流产率均无显著差异。作者认为黄体期雌二醇可谨慎减量。
要点
- HRT-FET周期中,黄体期雌二醇减量与常规黄体期支持相比临床结局相似。
- 减量组与维持组的生化妊娠率、临床妊娠率、着床率及流产率均无显著差异。
- 作者认为HRT-FET周期黄体期雌二醇可谨慎减量。
核心结论
- 黄体期雌二醇减量获得的临床结局与传统的黄体期支持相似,作者认为HRT-FET周期黄体期雌二醇可谨慎减量。
研究设计与样本
- 回顾性研究,纳入湘雅医院生殖医学中心2011年1月至2018年6月共6035个HRT-FET周期。
- 研究组为胚胎移植后12天起雌二醇减量的1632个HRT-FET周期,对照组为黄体期雌二醇维持常量的4403个HRT-FET周期,比较血清HCG阳性者的临床结局。
主要发现
- 生化妊娠率:减量组52.1% vs 维持组51.9%(P=0.864)。
- 临床妊娠率:减量组44.9% vs 维持组43.2%(P=0.249)。
- 着床率:减量组29.8% vs 维持组29.3%(P=0.591)。
- 流产率:减量组16.0% vs 维持组14.6%(P=0.379)。
临床怎么用
- 作者认为,HRT-FET周期胚胎移植后黄体期雌二醇可谨慎减量。
局限性
- 回顾性设计可能存在相关偏倚。
- 组间部分基线特征存在差异。
- 未比较两组间的活产率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Does oestrogen dose tapering during the luteal phase affect the clinical outcome after hormone replacement treatment-frozen-thawed embryo transfer (HRT-FET) cycles? SUMMARY ANSWER: Our results suggest that tapering oestrogen doses during the luteal phase results in similar clinical outcomes to those obtained with the traditional luteal phase support (LPS). WHAT IS KNOWN ALREADY: Traditional LPS with oestrogen and progesterone is considered necessary in HRT-FET cycles. However, case reports have shown successful clinical pregnancies and live births in the absence of oestrogen administration after embryo transfers. STUDY DESIGN, SIZE, DURATION: This was a retrospective study on 6035 HRT-FET cycles extending over 7 years from January 2011 to June 2018 at the reproductive medicine centre of Xiangya Hospital. PARTICIPANTS/MATERIALS, SETTING, METHODS: We compared the clinical outcomes of 1632 HRT-FET cycles with tapered oestrogen doses from 12 days after embryo transfer (study group) to those of 4403 HRT-FET cycles maintained on constant oestrogen doses during the luteal phase (control group) in the case of positive serum HCG test. MAIN RESULTS AND THE ROLE OF CHANCE: We found similar biochemical pregnancy rates (52.1% vs. 51.9, P = 0.864), clinical pregnancy rates (44.9% vs. 43.2%, P = 0.249), implantation rates (29.8% vs. 29.3%, P = 0.591) and miscarriage rates (16.0% vs. 14.6%, P = 0.379) between the studied groups. LIMITATIONS, REASONS FOR CAUTION: Retrospective, design-associated biases are possible. In addition, some baseline characteristics differed between groups. Finally, we did not compare live birth rates between groups. WIDER IMPLICATIONS OF THE FINDINGS: Our study showing similar outcomes between traditional LPS and oestrogen tapering during the luteal phase indicates that oestrogen may be cautiously tapered during the luteal phase after HRT-FET cycles. STUDY FUNDING/COMPETING INTEREST(S): This work was supported by the National Natural Science Foundation of China (grant no. 81401269) and the class General Financial Grant from the China Postdoctoral Science Foundation (grant no. 2017M620360). The authors declare that they have no competing interests. TRIAL REGISTRATION NUMBER: N/A.
引用
- Jing Z, Xi H, Qianling Z, et al. Oestrogen dose tapering during luteal phase does not affect clinical outcomes after hormone replacement treatment-frozen-thawed embryo transfer cycles: a retrospective analysis. Hum Reprod. 2019. PMID: 31310320. doi:10.1093/humrep/dez096
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。